Revance Therapeutics (NASDAQ:RVNC) Now Covered by StockNews.com

StockNews.com began coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a research note published on Saturday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Several other research analysts have also recently issued reports on RVNC. Needham & Company LLC reissued a “hold” rating on shares of Revance Therapeutics in a research note on Friday, November 8th. HC Wainwright reissued a “neutral” rating and set a $6.60 price target on shares of Revance Therapeutics in a research report on Friday, November 8th. Barclays decreased their price objective on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a report on Monday, December 23rd. Finally, Mizuho dropped their target price on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a report on Tuesday, December 10th. Nine investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $8.39.

Revance Therapeutics Stock Down 0.6 %

RVNC stock opened at $3.06 on Friday. Revance Therapeutics has a twelve month low of $2.30 and a twelve month high of $9.74. The firm has a market cap of $319.43 million, a price-to-earnings ratio of -1.59 and a beta of 0.81. The business’s fifty day simple moving average is $4.12 and its two-hundred day simple moving average is $4.49.

Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The business had revenue of $59.88 million for the quarter, compared to the consensus estimate of $67.73 million. Research analysts expect that Revance Therapeutics will post -1.57 EPS for the current year.

Institutional Trading of Revance Therapeutics

A number of institutional investors have recently modified their holdings of the company. Exome Asset Management LLC purchased a new stake in Revance Therapeutics during the third quarter valued at approximately $1,804,000. Oddo BHF Asset Management Sas acquired a new position in shares of Revance Therapeutics during the third quarter worth $3,763,000. Virtu Financial LLC purchased a new stake in shares of Revance Therapeutics during the 3rd quarter valued at $120,000. Wellington Management Group LLP acquired a new stake in shares of Revance Therapeutics in the 3rd quarter worth $2,315,000. Finally, State Street Corp grew its stake in Revance Therapeutics by 6.6% during the 3rd quarter. State Street Corp now owns 2,433,963 shares of the biopharmaceutical company’s stock worth $12,632,000 after buying an additional 150,323 shares during the last quarter. 97.70% of the stock is currently owned by institutional investors.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.